Marché mondial des traitements contre le mélanome – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des thérapies contre le mélanome

Selon les données de l’OMS, environ 132 000 cas de cancer de la peau surviennent chaque année. De plus, une diminution de 10 % des niveaux d’ozone devrait entraîner une augmentation de 4 500 cas de cancer de la peau dans le monde. L’incidence des allergies cutanées, du mélanome et d’autres cancers de la peau dans les pays en développement est élevée, ce qui constitue une opportunité pour les sociétés pharmaceutiques de gagner une plus grande part de marché dans ces régions. Les gènes et les rayons UV sont les principaux responsables du mélanome.

Data Bridge Market Research analyse le taux de croissance du marché des thérapies contre le mélanome au cours de la période de prévision 2023-2030. Le TCAC attendu du marché des thérapies contre le mélanome a tendance à être d'environ 16,30 % au cours de la période de prévision mentionnée. Le marché était évalué à 3,45 milliards USD en 2022 et devrait atteindre 11,55 milliards USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des thérapies contre le mélanome

Market Definition

Melanoma is the most hazardous type of skin cancer that develops in the melanocytes cells which produce melanin. Melanoma can also produce in the eyes and most rarely inside the body such as nose and throat. There are various risk factors for melanoma, including overexposure to the sun, a family history of melanoma, and having fair skin, among others. Melanoma is considered to be the deadliest of these three types of skin cancer.

Global Melanoma Therapeutics Market

Drivers

• Increasing Demand of Radiation Therapy

The radiation therapy is projected to show steady growth during the forecast period due to the growing number of advanced melanoma cases and the increasing use of radiation as an adjuvant therapy post-surgery. Radiation therapy is often used as a primary treatment. It is only administered to stage 4 patients who cannot be treated with surgery.

• Increase in Skin Cancer

According to records of WHO, about 132,000 cases of skin cancer occur each year. Additionally, a 10% reduction in ozone levels is projected to lead to an increase of 4,500 skin cancer cases worldwide. The incidence of skin allergies, melanoma, and other skin cancers in developing countries is more, that serves as an opportunity for many drug companies to gain a greater share in these regions. This is estimated to increase the demand for these drugs during the forecast period.

Opportunities

• Growing Regulatory Approvals By Authorizations

The high emphasis and increasing investment in highly developing efficient treatment options are most likely to significantly impact the market growth. Treatment recommendations depend on several factors, and the increasing number of regulatory approvals has considerably impacted the market growth. For instance, in 2021, Binimetinib, Braftovi, Aldesleukin, Cobimetinib Fumarate, Dabrafenib Mesylate, Cotellic were some of the approved drugs that are used for the treatment of cancer by FDA. The significance of major key players on introducing several innovative treatment options and drugs will support the market growth in the upcoming years.   

• Development of new Biologics

The major market players in the U.S., Europe, and Asia Pacific are focusing on developing several new biologics for the treatment of melanoma. For instance, in March 2017, Take a Novel Challenge for Drug Discovery (TaNeDS) was introduced by Daiichi Sankyo Company Limited, a collaborative project aimed at facilitating new drug development through various collaborations. In addition to this, it has a strategic research partnership with AgonOX, Inc. to explore innovative immunotherapy treatments for the market.

 Restraints/Challenges

• Unavailability of Appropriate Treatments

To treat many different types of cancers, there are times when all treatments are not available, particularly in underdeveloped countries. Severe patients need to be treated with many advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Therefore, it impedes the market growth.

• Increasing Rate of Patent Expiration Drugs

There are several drugs that lose expiry and it takes much time to get back the patent. Branded drugs are anticipated to lose their market share during the forecast period because of the patent expiration of notable brands such as Yervoy and Imlygic. Imlygic is projected to lose its patent protection in 2021, which will result in reduced revenue for Amgen, Inc. Likewise, Yervoy is estimated to lose its patent exclusivity in the U.S. in 2022 and Europe in 2020.

This melanoma therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the melanoma therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Melanoma Therapeutics Market

The pandemic has considerably affected various diagnostic methods due to numerous restrictions and risk exposure of comorbidity patients. A drastic reduction in skin biopsies was seen early in the COVID-19 pandemic, which unreasonably affected the elderly, females, and certain geographic regions. Though, government organizations have made efforts to contain the situation in the post-pandemic era.

Recent Development:

In 2020, AstraZeneca and Merck & Co. got FDA approval of the drug selumetinib to treat neurofibromatosis type 1, or NF1, a rare and characteristically inherited disease which causes tumors to grow inside nerve sheaths. Additionally, Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.

Global Melanoma Therapeutics Market Scope

The melanoma therapeutics market is segmented on the basis of type, stages, chemotherapy, drug type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Superficial Spreading Melanoma
• Nodular Melanoma
• Lentigo Maligna Melanoma
• Acral Lentiginous Melanoma
• Amelanotic Melanoma
• Others

Stages

• Stage 0
• Stage 1
• Stage 2
• Stage 3
• Stage 4
• Others

Chemotherapy

• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Immunotherapy
• Others

Drug Type

• Branded
• Generic

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Melanoma Therapeutics Market Regional Analysis/Insights

The melanoma therapeutics market is analyzed and market size insights and trends are provided by ype, stages, chemotherapy, drug type, distribution channel and end-user as referenced above.

The major countries covered in the melanoma therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for melanoma therapeutics market throughout the forecasted period due to the constant rise in skin cancer and increased demand for cost-efficient therapeutics.

North America dominates the market due to the presence of high healthcare expenditure and favorable reimbursement policies for treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Melanoma Therapeutics Market Share Analysis

Le paysage concurrentiel du marché des thérapies contre le mélanome fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des thérapies contre le mélanome.

Les principaux acteurs opérant sur le marché des thérapies contre le mélanome comprennent :

• Johnson & Johnson Private Limited (États-Unis)
• Mylan NV (États-Unis)
• Sun Pharmaceutical Industries Limited (Inde)
• Sanofi SA (France)
• Bayer AG (Allemagne)
• Lilly (États-Unis)
• Merck & Co., Inc. (États-Unis)
• GSK plc (Royaume-Uni)
• Novartis SA (Suisse)
• AbbVie Inc. (États-Unis)
• Les Compagnies de Santé Bausch Inc. (Canada)
• F. Hoffmann-La Roche SA (Suisse)
• Amgen Inc. (États-Unis)
• Société Bristol-Myers Squibb (États-Unis)
• Novartis SA (Suisse)
• Genentech, Inc (États-Unis)
• AstraZeneca (Royaume-Uni)
• DAIICHI SANKYO COMPANY, LIMITED (Japon)
• AB Science (France)
• AgonOX (États-Unis)
• Eisai Co., Ltd (Japon)
• Pfizer, Inc. (États-Unis)

SKU-57316